







an Open Access Journal by MDPI

Current Development of Vaccines for Respiratory Viral Infection

Guest Editor:

Dr. Ting Shi

Edinburgh Medical School, Edinburgh, UK

Deadline for manuscript submissions:

31 May 2024

Message from the Guest Editor

Dear Colleagues,

Viral respiratory tract infections constitute a substantial disease burden in the population, particularly among young children and older adults. More than 25 viruses have been linked to respiratory infections, including common respiratory pathogens such as rhinovirus (RV), respiratory syncytial virus (RSV), influenza virus (Flu), human metapneumovirus (hMPV), parainfluenza viruses (PIV) and human coronaviruses (CoVs). This Special Issue of Vaccines focuses on the most recent progress and current vaccine development trends in the field of respiratory viral infection. We invite you to contribute with an original research article, review or perspective on the latest research to highlight novel experimental vaccine candidates, scientific data on supporting strategies, immune responses elicited by a novel vaccine and concerns and optimisations relating vaccine strategies. This Special Issue emphasises major infectious diseases caused by respiratory viruses, but related topics on co-infections are also welcomed. We look forward to receiving your contributions.

Dr. Ting Shi Guest Editor







IMPACT FACTOR 7.8





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with <u>article processing charges (APC)</u> paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us